Join to View Full Profile
300 Pasteur DrA343Stanford, CA 94305
Phone+1 650-725-0773
Dr. Goodyear is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Neurology, 2008 - 2011- Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2007 - 2008
Tufts University School of MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2009 - 2016
Clinical Trials
- Vitamin D Supplementation in Multiple Sclerosis Start of enrollment: 2012 Mar 01
- High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases Start of enrollment: 2014 Apr 01
- Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Start of enrollment: 2014 Mar 01
Publications & Presentations
PubMed
- 3 citationsImproving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.Jennifer S Graves, Marius Thomas, Jun Li, Anuja R Shah, Alexandra Goodyear
Therapeutic Advances in Neurological Disorders. 2022-01-01 - 328 citationsOfatumumab versus Teriflunomide in Multiple SclerosisStephen L. Hauser, Amit Bar-Or, Jeffrey A. Cohen, Giancarlo Comi, Jorge Correale
The New England Journal of Medicine. 2020-08-05 - 75 citationsProtective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoproteinKatja Herges, Brigit A. de Jong, Ilan Kolkowitz, Caitlin Dunn, Gil Mandelbaum
Multiple Sclerosis. 2012-02-16
Journal Articles
- Ofatumumab Versus Teriflunomide in Multiple SclerosisStephen L Hauser, Amit Bar-Or, Patricia K Coyle, Alexandra Goodyear, The New England Journal of Medicine
Authored Content
- Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020
- Ofatumumab Versus Teriflunomide in Multiple SclerosisAugust 2020
Professional Memberships
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
